These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 11380627)

  • 1. Safety and efficacy of a new recombinant FVIII formulated with sucrose (rFVIII-FS) in patients with haemophilia A: a long-term, multicentre clinical study in Japan.
    Yoshioka A; Shima M; Fukutake K; Takamatsu J; Shirahata A;
    Haemophilia; 2001 May; 7(3):242-9. PubMed ID: 11380627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sucrose formulated recombinant human antihemophilic factor VIII is safe and efficacious for treatment of hemophilia A in home therapy--International Kogenate-FS Study Group.
    Abshire TC; Brackmann HH; Scharrer I; Hoots K; Gazengel C; Powell JS; Gorina E; Kellermann E; Vosburgh E
    Thromb Haemost; 2000 Jun; 83(6):811-6. PubMed ID: 10896230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stability, efficacy, and safety of continuously infused sucrose-formulated recombinant factor VIII (rFVIII-FS) during surgery in patients with severe haemophilia.
    Martinowitz U; Luboshitz J; Bashari D; Ravid B; Gorina E; Regan L; Stass H; Lubetsky A
    Haemophilia; 2009 May; 15(3):676-85. PubMed ID: 19298381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of a sucrose-formulated recombinant factor VIII product for the treatment of previously treated patients with haemophilia A in China.
    Shi J; Zhao Y; Wu J; Sun J; Wang L; Yang R
    Haemophilia; 2007 Jul; 13(4):351-6. PubMed ID: 17610547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics, prophylactic effects, and safety of a new recombinant FVIII formulated with sucrose (BAY 14-2222) in Japanese patients with hemophilia A.
    Shirahata A; Fukutake K; Takamatsu J; Shima M; Yoshioka A
    Int J Hematol; 2000 Jul; 72(1):101-7. PubMed ID: 10979218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of sucrose-formulated full-length recombinant factor VIII: experience in the standard clinical setting.
    Musso R; Santagostino E; Faradji A; Iorio A; van der Meer J; Ingerslev J; Lambert T; Maas-Enriquez M; Gorina E;
    Thromb Haemost; 2008 Jan; 99(1):52-8. PubMed ID: 18217134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Full-length sucrose-formulated recombinant factor VIII for treatment of previously untreated or minimally treated young children with severe haemophilia A: results of an international clinical investigation.
    Kreuz W; Gill JC; Rothschild C; Manco-Johnson MJ; Lusher JM; Kellermann E; Gorina E; Larson PJ;
    Thromb Haemost; 2005 Mar; 93(3):457-67. PubMed ID: 15735795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. European data of a clinical trial with a sucrose formulated recombinant factor VIII in previously treated haemophilia A patients.
    Rothschild C; Scharrer I; Brackmann HH; Stieltjes N; Vicariot M; Torchet MF; Effenberger W
    Haemophilia; 2002 Mar; 8 Suppl 2():10-4. PubMed ID: 11966846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human recombinant DNA-derived antihaemophilic factor (factor VIII) in the treatment of haemophilia A: conclusions of a 5-year study of home therapy. The KOGENATE Study Group.
    Seremetis S; Lusher JM; Abildgaard CF; Kasper CK; Allred R; Hurst D
    Haemophilia; 1999 Jan; 5(1):9-16. PubMed ID: 10215942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical evaluation of a recombinant factor VIII preparation (Kogenate) in previously untreated patients with hemophilia A.
    Yoshioka A; Fukutake K; Takamatsu J; Shirahata A;
    Int J Hematol; 2003 Dec; 78(5):467-74. PubMed ID: 14704043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Continuous infusion of recombinant factor VIII formulated with sucrose in surgery: non-interventional, observational study in patients with severe haemophilia A.
    Meijer K; Rauchensteiner S; Santagostino E; Platokouki H; Schutgens RE; Brunn M; Tueckmantel C; Valeri F; Schinco PC
    Haemophilia; 2015 Jan; 21(1):e19-25. PubMed ID: 25458982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results from a large multinational clinical trial (guardian™1) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia A: safety and efficacy.
    Lentz SR; Misgav M; Ozelo M; Salek SZ; Veljkovic D; Recht M; Cerqueira M; Tiede A; Brand B; Mancuso ME; Seremetis S; Lindblom A; Martinowitz U
    Haemophilia; 2013 Sep; 19(5):691-7. PubMed ID: 23647704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An observational study of sucrose-formulated recombinant factor VIII for Japanese patients with haemophilia A.
    Delumeau JC; Ikegawa C; Yokoyama C; Haupt V
    Thromb Haemost; 2008 Jul; 100(1):32-7. PubMed ID: 18612535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of liposomal dose in recombinant factor VIII reconstituted with pegylated liposomes for the treatment of patients with severe haemophilia A.
    Spira J; Plyushch OP; Andreeva TA; Khametova RN
    Thromb Haemost; 2008 Sep; 100(3):429-34. PubMed ID: 18766258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of pegylated full-length recombinant factor VIII with extended half-life for perioperative haemostasis in haemophilia A patients.
    Brand B; Gruppo R; Wynn TT; Griskevicius L; Lopez Fernandez MF; Chapman M; Dvorak T; Pavlova BG; Abbuehl BE
    Haemophilia; 2016 Jul; 22(4):e251-8. PubMed ID: 27328112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and pharmacokinetics of a recombinant factor VIII with pegylated liposomes in severe hemophilia A.
    Powell JS; Nugent DJ; Harrison JA; Soni A; Luk A; Stass H; Gorina E
    J Thromb Haemost; 2008 Feb; 6(2):277-83. PubMed ID: 18039351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First and next generation native rFVIII in the treatment of hemophilia A. What has been achieved? Can patients be switched safely?
    Suiter TM
    Semin Thromb Hemost; 2002 Jun; 28(3):277-84. PubMed ID: 12098089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of prophylaxis with once-weekly BAY 79-4980 compared with thrice-weekly rFVIII-FS in haemophilia A patients. A randomised, active-controlled, double-blind study.
    Powell J; Martinowitz U; Windyga J; Di Minno G; Hellmann A; Pabinger I; Maas Enriquez M; Schwartz L; Ingerslev J;
    Thromb Haemost; 2012 Nov; 108(5):913-22. PubMed ID: 23014711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of standard prophylaxis versus on-demand treatment with bayer's sucrose-formulated recombinant FVIII (rFVIII-FS) in Chinese children with severe hemophilia A.
    Zhao Y; Xiao J; Yang R; Wu R; Hu Y; Beckmann H; Wu J; Hou Q; Sun J
    Pediatr Hematol Oncol; 2017 Apr; 34(3):138-148. PubMed ID: 28727494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation between endogenous VWF:Ag and PK parameters and bleeding frequency in severe haemophilia A subjects during three-times-weekly prophylaxis with rFVIII-FS.
    Lalezari S; Martinowitz U; Windyga J; Enriquez MM; Delesen H; Schwartz L; Scharrer I
    Haemophilia; 2014 Jan; 20(1):e15-22. PubMed ID: 24252058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.